Dr. Daniel Von Hoff, a principal investigator in the Phase I clinical trial at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, says the drug ASG-5ME is a targeted compound meant to kill cancer cells selectively, a center release reported Wednesday.
Pancreatic cancer, fast-growing and difficult to treat, is the fourth-leading cause of cancer death in the United States.
"ASG-5ME is intended for pancreatic cancer patients who do not have a good prognosis with currently available therapies," Von Hoff said.
The new compound uses a monoclonal antibody against a target found in more than 90 percent of pancreatic cancer patients to selectively kill the pancreatic cancer cells, the release said.
"It is a precision approach that is designed to avoid non-targeted cells, increasing anti-tumor activity in preclinical models and potentially reducing the toxic effects of traditional chemotherapy" Von Hoff said.